Hauschild Axel, Egberts Friederike, Russo Paul, Kähler Katharina C
Department of Dermatology, University of Kiel, Kiel, Germany.
Cancer Metastasis Rev. 2006 Jun;25(2):253-6. doi: 10.1007/s10555-006-8505-5.
Approximately 20 to 25% of patients with malignant melanoma will die of metastatic disease. The current standards of care for advanced metastatic melanoma (stage IV, AJCC classification) are poor. To date, randomized trials have failed to demonstrate that one regimen is better than another. It is therefore crucial that patients with disseminated malignant melanoma be recruited into clinical trials. In recent years, there have been impressive advances in our knowledge of the biology and nature of cancer development and the growth and progression to metastasis. The approach "from bench to bedside" is current reality in the treatment of several solid tumors and hematologic malignancies. The identification of new targets to facilitate individualized melanoma treatment is now an important issue. This article will give an overview of recent developments in clinical trials of targeted therapies in metastatic melanoma patients.
大约20%至25%的恶性黑色素瘤患者会死于转移性疾病。目前针对晚期转移性黑色素瘤（美国癌症联合委员会[AJCC]分期为IV期）的护理标准很差。迄今为止，随机试验未能证明一种治疗方案优于另一种。因此，将播散性恶性黑色素瘤患者纳入临床试验至关重要。近年来，我们对癌症发生的生物学和本质以及转移的生长和进展的认识取得了令人瞩目的进展。“从实验室到临床”的方法在几种实体瘤和血液系统恶性肿瘤的治疗中已成为现实。确定新的靶点以促进黑色素瘤个体化治疗现在是一个重要问题。本文将概述转移性黑色素瘤患者靶向治疗临床试验的最新进展。
